Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY21QW
|
|||
| Drug Name |
RGX-121
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Mucopolysaccharidosis [ICD-11: 5C56.3; ICD-9: 277.5] | Phase 1/2 | [1] | |
| Company |
REGENXBIO
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Iduronate 2-sulfatase (IDS) | Target Info | Replacement | [2] |
| BioCyc | Dermatan sulfate degradation (metazoa) | |||
| KEGG Pathway | Glycosaminoglycan degradation | |||
| Metabolic pathways | ||||
| Lysosome | ||||
| Reactome | HS-GAG degradation | |||
| CS/DS degradation | ||||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04571970) RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of REGENXBIO. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.